Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shorter radiation regimen aims to improve sarcoma treatment

NCT ID NCT07507773

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This phase 2 trial is testing a shorter, more intense radiation schedule given before surgery for soft tissue sarcoma in the arms, legs, or trunk. The goal is to see if this approach can keep the cancer from coming back in the same spot. About 135 adults will receive 15 radiation sessions over 3 weeks, followed by surgery, and then be monitored for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
moderately hypofractionated radiotherapy (15 sessions over 3 weeks)
What this could lead to
If successful, this shorter radiation schedule could become a standard option before surgery for soft tissue sarcoma, reducing treatment time while maintaining tumor control.
What could go wrong
This is a phase 2 trial with only 135 participants, so results are preliminary. The shorter radiation course may not control the tumor as well as standard longer regimens, and side effects could differ.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jun 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged ≥ 18 years ; * Localised sarcoma of a limb, the root of a limb, or the trunk wall ; * Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ; * Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ; * Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ; * Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ; * Affiliation to the French National Social Security System ; * Informed and signed consent Exclusion Criteria: * Metastatic disease (including local lymph node diffusion) ; * Visceral or retroperitoneal sarcoma ; * Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ; * Indication of neoadjuvant or adjuvant chemotherapy ; * Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ; * Pregnant or breastfeeding women ; * Patients under protective measures ; * Patient refusal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma (excluding gist) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Soft tissue sarcoma (excluding gist) Soft tissue sarcoma adult Soft tissue sarcoma of the limb Soft tissue sarcoma of the trunk and extremities

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Oscar Lambret

    RECRUITING

    Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.